Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

More than 300 new hypertension genes discovered

07.03.2005


A genome-wide scan in hypertension in the East Finland founder population has re-affirmed the majority of genes previously known to be associated with hypertension. The new genes discovered include also ones, which appear to give humans a strong protection against hypertension. The scan was conducted by a novel approach.



The DNA samples used in the study were collected in the 1980’s from a genetically-homogeneous population that can be accurately traced back to a few hundred founders in the 1600’s.

The Jurilab team used a novel approach. The Jurilab gene discovery team typed over 100,000 single-nucleotide-polymorphisms covering the majority of structural blocks in the genome of Eastern Finns, who share exceptionally large genomic regions. The study was supported by Tekes and carried out in collaboration with the University of Kuopio in East Finland.


The study confirms Jurilab’s previous assumptions concerning the total number of disease-related genes involved in hypertension, and gives invaluable insight into the interplay of different genes and new pathways in hypertension.

"These discoveries open up a new chapter in the development of predictive tests and much improved therapeutics for hypertension", said professor Jukka T. Salonen, Jurilab’s chief scientific officer. "We have also shown that human studies are relevant and cannot be replaced by animal models".

"Jurilab plans to commercialize the findings rapidly with our partners starting with the first hypertension molecular diagnostic test and followed by other exciting products in diagnostics and drug development", said Kari Paukkeri, CEO of the company.

Hypertensions prevalence rising

Between a quarter and a third of adults in developed countries suffer from hypertension, and this prevalence is on the rise. Hypertension starts to damage the heart, arteries, brains and kidneys already in childhood but is detectable by blood pressure measurements at the earliest in the adulthood.

Also, most current antihypertensive drugs are not usable by all hypertension patients because of lack of efficacy and adverse reactions. As these differences between individuals are of genetic origin, molecular diagnostic tests can help the physician to start treatment early and to select the drug of choice without the expensive and harmful trial-and-error method.

Mira Banerjee | alfa
Further information:
http://www.tekes.fi

More articles from Life Sciences:

nachricht Decoding the genome's cryptic language
27.02.2017 | University of California - San Diego

nachricht New risk factors for anxiety disorders
24.02.2017 | Julius-Maximilians-Universität Würzburg

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

Sandia uses confined nanoparticles to improve hydrogen storage materials performance

27.02.2017 | Interdisciplinary Research

Decoding the genome's cryptic language

27.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>